Hangzhou Zhihe Dangu Biomedicine

Hangzhou Zhihe Dangu Biomedicine, operating under the brand SmartNucl, is a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals. The company utilizes a proprietary single-domain antibody (nanobody) platform to engineer highly specific diagnostic imaging agents and targeted radionuclide therapies. Its lead candidate, SNC-002, is a PD-L1-targeted molecular imaging tracer designed to predict immunotherapy response in cancer patients. SmartNucl's pipeline spans various high-value oncology targets, including HER2 and PSMA, aiming to advance the field of theranostics through precision nuclear medicine. The company is supported by prominent venture capital firms and maintains its own GMP-compliant radiopharmaceutical production facilities.